Literature DB >> 17171364

Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.

T Nakamura, T Sugaya, H Koide.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17171364     DOI： 10.1007/s00125-006-0545-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

Review 1.  Tubulointerstitial damage and progression of renal failure.

Authors:  Bernardo Rodríguez-Iturbe; Richard J Johnson; Jaime Herrera-Acosta
Journal:  Kidney Int Suppl       Date:  2005-12       Impact factor: 10.545

2.  Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.

Authors:  Tsukasa Nakamura; Takeshi Sugaya; Yasuhiro Kawagoe; Yoshihiko Ueda; Shiwori Osada; Hikaru Koide
Journal:  Diabetes Care       Date:  2005-11       Impact factor: 19.112

3.  Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.

Authors:  Otilie Weinbergová; Rudolf Metelka; Jirí Vymetal; Karel Konecný; Zdena Kosatíková
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2004-07       Impact factor: 1.245

4.  Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies.

Authors:  Pedro Aranda; Julian Segura; Luis M Ruilope; Francisco J Aranda; Miguel A Frutos; Verónica López; Eduardo López de Novales
Journal:  Am J Kidney Dis       Date:  2005-12       Impact factor: 8.860

5.  Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial.

Authors:  Atsuko Kamijo; Takeshi Sugaya; Akihisa Hikawa; Masaya Yamanouchi; Yasunobu Hirata; Toshihiko Ishimitsu; Atsushi Numabe; Masao Takagi; Hiroshi Hayakawa; Fumiko Tabei; Tokuichiro Sugimoto; Naofumi Mise; Kenjiro Kimura
Journal:  J Lab Clin Med       Date:  2005-03

6.  Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering.

Authors:  Yuko Izuhara; Masaomi Nangaku; Reiko Inagi; Naoto Tominaga; Toru Aizawa; Kiyoshi Kurokawa; Charles van Ypersele de Strihou; Toshio Miyata
Journal:  J Am Soc Nephrol       Date:  2005-10-19       Impact factor: 10.121

7.  Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.

Authors:  Atsuko Kamijo; Takeshi Sugaya; Akihisa Hikawa; Masaya Yamanouchi; Yasunobu Hirata; Toshihiko Ishimitsu; Atsushi Numabe; Masao Takagi; Hiroshi Hayakawa; Fumiko Tabei; Tokuichiro Sugimoto; Naofumi Mise; Masao Omata; Kenjiro Kimura
Journal:  Mol Cell Biochem       Date:  2006-03       Impact factor: 3.396

Review 8.  The role of renal proximal tubular cells in diabetic nephropathy.

Authors:  Aled O Phillips
Journal:  Curr Diab Rep       Date:  2003-12       Impact factor: 5.430
  8 in total
  6 in total

1.  Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury.

Authors:  Michael A Ferguson; Vishal S Vaidya; Sushrut S Waikar; Fitz B Collings; Kelsey E Sunderland; Costas J Gioules; Joseph V Bonventre
Journal:  Kidney Int       Date:  2009-11-25       Impact factor: 10.612

Review 2.  Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists.

Authors:  Jun Wada; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2009-04-11       Impact factor: 2.801

3.  Distinct roles of urinary liver-type fatty acid-binding protein in non-diabetic patients with anemia.

Authors:  Naohiko Imai; Takashi Yasuda; Atsuko Kamijo-Ikemori; Yugo Shibagaki; Kenjiro Kimura
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

4.  Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes.

Authors:  Hiroyuki Ito; Hitomi Yamashita; Mina Nakashima; Akifusa Takaki; Chiduko Yukawa; Suzuko Matsumoto; Takashi Omoto; Masahiro Shinozaki; Shinya Nishio; Mariko Abe; Shinichi Antoku; Mizuo Mifune; Michiko Togane
Journal:  J Clin Med Res       Date:  2017-02-21

5.  Tubular and glomerular injury in diabetes and the impact of ACE inhibition.

Authors:  Stine E Nielsen; Takeshi Sugaya; Lise Tarnow; Maria Lajer; Katrine J Schjoedt; Anne Sofie Astrup; Tsuneharu Baba; Hans-Henrik Parving; Peter Rossing
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 19.112

6.  Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes.

Authors:  Nicolae M Panduru; Carol Forsblom; Markku Saraheimo; Lena Thorn; Angelika Bierhaus; Per M Humpert; Per-Henrik Groop
Journal:  Diabetes Care       Date:  2013-02-01       Impact factor: 19.112
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.